MedTrace Logo

Azilsartan in Chinese Patients With Mild and Moderate Hypertension

NCT02609490 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 304

Last updated 2018-09-04

No results posted yet for this study

Summary

A phase 3 clinical study to evaluate the safety and efficacy of Azilsartan in Chinese hypertension patients

Conditions

Interventions

DRUG

Azilsartan tablets

20mg/tablet

DRUG

Azilsartan placebo tablets

placebo tablet

DRUG

Olmesartan medoxomil tablets

20mg/tablet

DRUG

olmesartan medoxomil placebo tablets

placebo tablet

Sponsors & Collaborators

  • Lee's Pharmaceutical Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-02-28
Completion
2018-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02609490 on ClinicalTrials.gov